Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7027749 | 0.93 | KDM4E (0.60) | MAPTKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL7030422 | 0.92 | ABCB1 (0.55) | MAPTKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL7026426 | 0.92 | MAPT (0.52) | MAPTKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL7028453 | 0.91 | ABCB1 (0.47) | MAPTABCB1PDPK1TTRALOX5 | |
| SCHEMBL744489 | 0.91 | ABCB1 (0.56) | MAPTKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL7029762 | 0.90 | ABCB1 (0.55) | MAPTKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL7029785 | 0.88 | KDM4E (0.55) | MAPTKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL7027864 | 0.87 | ABCB1 (0.56) | MAPTKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL7027820 | 0.86 | ABCB1 (0.56) | MAPTKDM4ELMNASMN1; SMN2HTT | |
| SCHEMBL7027902 | 0.84 | MAPT (0.51) | MAPTKDM4ELMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | CDK6, CDK5, CDK4 | MAPT 3525/4885KDM4E 843/4885LMNA 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.